Pathologic and Oncologic Outcomes in Locally Advanced Gastric Cancer with Neoadjuvant Chemotherapy or Chemoradiotherapy

Ji Yeong An, Hyoung-Il Kim, Jae-Ho Cheong, Woo Jin Hyung, Choong Bae Kim, and Sung Hoon Noh
Department of Surgery, Yonsei University College of Medicine, Seoul, Korea.

Purpose: Although neoadjuvant therapy has been accepted as a treatment option in locally-advanced gastric cancer, its prognostic value has been difficult to evaluate.

Materials and Methods: Seventy-four gastric cancer patients who underwent gastrectomy after neoadjuvant treatment were divided into two groups according to the pathologic response: favorable (ypT0) and others (ypT1-4). The clinicopathologic characteristics, predictive factors for pathologic response, and oncologic outcome were evaluated.

Results: Eleven patients (14.8%) demonstrated ypT0 and the remaining 63 patients (85.2%) were ypT1-4. Chemoradiotherapy (CCRTx) rather than chemotherapy (CTx) was the only predictive factor for a favorable pathologic response. Chemotherapeutic factors and tumor marker levels did not predict pathologic response. The 1-, 2-, and 3-year disease-free survivals were 83.4%, 70%, and 52.2%. The 1-, 3-, 5-year overall survivals were 88.5%, 67.5%, and 51.2%, respectively. Although a complete pathologic response (ypT0N0M0) was achieved in 7 patients, 28.6% of them demonstrated recurrence of the tumor within 6 months after curative surgery.

Conclusion: CCRTx rather than CTx appears to be more effective for achieving good pathologic response. Although favorable pathologic response has been achieved after neoadjuvant treatment, the survival benefit remains controversial.

Key Words: Gastric cancer, neoadjuvant chemotherapy, neoadjuvant chemoradiotherapy, gastrectomy, pathologic response, prognosis

INTRODUCTION

Although complete surgical removal represents the only curative treatment for gastric cancer, preoperative chemotherapy (CTx) and chemoradiotherapy (CCRTx) have been increasingly used over the past decades for advanced gastric cancer with the goals of tumor downstaging and increasing the rates of curative surgical resection and survival.

The benefits of preoperative CTx and CCRTx in gastric cancer have been widely reported in Western trials. For locally-advanced gastric cancer, the R0 resection rate was 70% to 80%, and the complete pathologic response rate was 15% to 30%. However, in Eastern countries, including Korea and Japan, the primary treatment for locally-advanced gastric cancer is surgical resection. Many surgeons prefer the aggressive or extended surgical resection to medical treatment and worry that pa-
For the combination of three regimens, 5-FU, platinum and taxol were used. Patients were divided into three groups according to the total number of cycles of preoperative CTx: 1) ≤3 cycles; 2) 4-6 cycles; and 3) >6 cycles. Patients received either CTx (n=55) or CCRTx (n=19), and there was no crossover between groups. The total preoperative radiotherapy dose was 4500 cGy.

Surgical treatment included standard or extended gastrectomy with lymph node dissection according to the guidelines of the Japanese Gastric Cancer Association.5

Because the standard extent of lymph node dissection in advanced gastric cancer is D2, most patients received D2 lymph node dissection. However, some patients with noncurative resection received D1+b lymph node dissection. Extended gastrectomy included resection of adjacent organs, such as the spleen, colon, pancreas, small bowel, and liver, in addition to the subtotal or total gastrectomy. R0 resection indicates a complete resection with no gross evidence of residual tumor. R1 resection refers to tumor involvement of the margins of the resected tissue when viewed microscopically, and R2 resection indicates that portions of visible tumor were not removed.

Evaluation
Clinicopathologic characteristics, such as sex, age, American Society of Anesthesiologists (ASA) score, tumor location, histologic type, number of chemotherapeutic regimens, number of chemotherapeutic cycles, and laboratory markers, were examined based on ypT status. Laboratory data included carcinoembryonic antigen, cancer antigen 72-4, cancer antigen, white blood cell count, neutrophil and lymphocyte count. The initial pretreatment values and preoperative values after CTx or CCRTx were checked. Surgical outcomes including the extent of resection, extent of lymph node dissection, operative time, and postoperative complications were also evaluated.

After R0 resection, the incidence of tumor recurrence and recurrence pattern were evaluated according to the ypT and ypN status. The tumor recurrence patterns were classified as lymphatic, peritoneal, hematogenous, and multiple recurrences. The evaluation of the pathologic stage was based on the 7th edition of the International Union Against Cancer Classification.6 The overall survival (OS) rate was calculated from the day of surgical resection until the time of death.

Statistical analysis
Statistical analysis was performed using SPSS® version
9 patients (12.7%) could not undergo R0 resection: peritoneal seeding (n=8) and positive margins on resection (n=1). The mean number of retrieved lymph nodes was 39.0±17.7 in the ypT0 group and 38.0±17.3 in the ypT1-4 group. There were no significant differences in postoperative complications and the duration of hospital stay between the two groups.

Survival of patients according to ypT and ypN status
Over the median 25-month follow-up, the 1-, 2-, and 3-year disease-free survival rates were 83.4%, 70.0%, and 52.2%, respectively. The 1-, 3-, and 5-year overall survival rates were 88.5%, 67.5%, and 51.2%, respectively. The survival curves were plotted for the ypT and ypN status (Figs. 1 and 2). The survival curve for ypN status reflected patients’ prognoses better than ypT status. The modality of preoperative treatment (CCRTx vs. CTx) and the postoperative chemotherapy were not associated with patient survival.

Tumor recurrence after R0 resection
As shown in Table 3, patients were divided according to the ypT and ypN status and evaluated for tumor recurrence. Among 7 patients with ypT0N0, 2 (28%) patients showed tumor recurrence 4.7 months and 6.1 months after radical gastrectomy. The 2 patients with tumor recurrence were among the 5 patients who did not receive postoperative CTx. Neither of the 2 patients who received postoperative CTx showed tumor recurrence in patients with ypT0N0. Among the 3 patients with ypT0N1, only the one patient who did not receive postoperative CTx had a tumor relapse.

None of the patients with ypT1N0 (n=3) showed recurrence, and only 1 of 5 patients with ypT2N0 exhibited tumor recurrence. Recurrence rates were 33% to 50% in patients with ypT3 according to the ypN status. Recurrence rates ranged from 25% to 100% in those patients with ypT4. Tumor recurrence following gastrectomy generally occurred within a few months in most patients.

DISCUSSION
Gastrectomy with D2 lymph node dissection and extended surgery for resection of involved organs is the current standard of care for advanced gastric cancer.5,7,8 In recent years, a multidisciplinary treatment approach, including perioperative CTx, radiotherapy, and targeted therapy, has emerged for advanced gastric cancer, resulting in increased curability
Outcome of Neoadjuvant Treatment in AGC

and improved survival. Recent studies have suggested that neoadjuvant CTx in patients with unresectable, locally-advanced or metastatic gastric cancer can offer a chance for curative resection and improved survival.9,10

In the present study, we focused on identifying clinical factors predictive of an excellent response to preoperative CTx or CCRTx. As shown in Table 1, several clinicopathological factors were analyzed to find the predictive factor for favorable response to preoperative treatment. We found that histological type, preoperative chemotherapeutic regimens, and tumor markers were not associated with a favorable response. The only factor related to the favorable response was the type of preoperative treatment; either CTx or CCRTx. Although our curative resection rate was 87.8% (65 out of 74 patients), which is similar to other studies,2-4 our rate of complete pathologic response was only 9.4% (7 out of 74 pa-

| Table 1. Comparison of Preoperative Clinical, Therapeutic, and Tumor Features |
|---------------------------------|-----------------|-----------------|-----------------|
|                                | ypT0 (n=11)     | ypT1-4 (n=63)   | p value*       |
| Sex                            |                 |                 | 0.740          |
| Male                           | 7 (14.0)        | 43 (86.0)       |                 |
| Female                         | 4 (16.7)        | 20 (83.3)       |                 |
| Age (yrs)                      | 61.2±9.4        | 55.3±11.7       | 0.105†         |
| ASA score                      |                 |                 | 0.367          |
| 1                              | 8 (13.8)        | 50 (86.2)       |                 |
| 2                              | 2 (14.3)        | 12 (85.7)       |                 |
| 3                              | 1 (50.0)        | 1 (50.5)        |                 |
| Tumor location (in stomach)    |                 |                 | 0.649          |
| Upper                          | 3 (13.0)        | 20 (87.0)       |                 |
| Middle                         | 1 (9.1)         | 10 (90.9)       |                 |
| Lower                          | 7 (19.4)        | 29 (80.6)       |                 |
| Entire                         | 0 (0)           | 4 (100)         |                 |
| Histology                      |                 |                 | 0.740          |
| Differentiated                 | 3 (12.0)        | 22 (88.0)       |                 |
| Undifferentiated               | 8 (16.3)        | 41 (65.1)       |                 |
| Initial adjacent organ invasion |                 |                 | 1.000          |
| Absent                         | 6 (14.0)        | 37 (86.0)       |                 |
| Present                        | 5 (16.1)        | 26 (83.9)       |                 |
| Preop CTx vs. CCRTx            |                 |                 | 0.027†         |
| CTx only                       | 5 (9.1)         | 50 (90.9)       |                 |
| CCRTx                          | 6 (31.6)        | 13 (68.4)       |                 |
| No. of preop CTx regimens      |                 |                 | 0.331†         |
| 2 regimens                     | 8 (19.0)        | 34 (81.0)       |                 |
| 3 regimens                     | 3 (9.4)         | 29 (90.6)       |                 |
| Total cycles of preop CTx      |                 |                 | 0.543†         |
| ≤3                             | 6 (54.5)        | 31 (49.2)       |                 |
| 4-6                            | 2 (8.7)         | 21 (91.3)       |                 |
| >6                             | 3 (21.4)        | 11 (78.6)       |                 |
| Laboratory data                |                 |                 |                 |
| Initial CEA (ng/mL)            | 4.5±5.4         | 40.6±153.9      | 0.972†         |
| Preop CEA (ng/mL)              | 1.7±0.9         | 5.8±19.1        | 0.212†         |
| Initial CA72-4 (U/mL)          | 4.2±3.6         | 23.3±57.8       | 0.688†         |
| Preop CA72-4 (U/mL)            | 3.1±2.7         | 13.9±36.1       | 0.212†         |
| Initial CA19-9 (U/mL)          | 9.7±14.5        | 366.8±1290.6    | 0.166†         |
| Preop CA19-9 (U/mL)            | 78.9±223.2      | 112.4±519.6     | 0.542†         |

ASA, American Society of Anesthesiologists; CA, cancer antigen; CEA, carcinoembryonic antigen; CT, computed tomography; CTx, chemotherapy; CCRTx, chemoradiotherapy; EUS, endoscopic ultrasound.

*Chi-square.
†Initial adjacent organ invasion was evaluated by abdomen-pelvis CT scan and/or EUS before CTx or CCRTx.
‡Mann-Whitney U test, mean±standard deviation. Significant values are indicated in bold face. Values in parentheses are percentages.
response rate was lower than the reported 15% to 30% in previous prospective studies. \(^1\text{-}^3\) Overall, we were able to identify ypT0 patients as those patients likely to have a favorable outcome.

### Table 2. Surgical Outcomes and Pathologic Results According to ypT Status

|                        | ypT0 (n=11) | ypT1-4 (n=63) | \(p\) value* |
|------------------------|------------|---------------|--------------|
| **Resection extent**   |            |               | 0.161        |
| Subtotal               | 7 (63.6)   | 24 (38.1)     |              |
| Total                  | 4 (36.4)   | 27 (42.9)     |              |
| Extended               | 0 (0)      | 12 (19.0)     |              |
| **Extent of LND**      |            |               | 0.387        |
| <D2                    | 1 (9.1)    | 2 (3.2)       |              |
| \(\geq D2\)            | 10 (90.9)  | 61 (96.8)     |              |
| **Curability**         |            |               | 0.409        |
| R0                     | 11 (100)   | 54 (85.7)     |              |
| R1 R2                  | 0 (0)      | 9 (12.7)      |              |
| **Operation time (min)** | 184.5±105.3 | 192.0±45.1 | 0.821†        |
| **Blood loss (g)**     | 206.2±205.1 | 194.1±279.6 | 0.892†        |
| **Transfusion**        |            |               | 0.277        |
| No                     | 10 (90.9)  | 62 (98.4)     |              |
| Yes                    | 1 (9.1)    | 1 (1.6)       |              |
| **No. of retrieved LNs** | 39.0±17.7  | 38.0±17.3    | 0.781†        |
| **ypN status**         |            |               | 0.027        |
| ypN0                   | 7 (63.6)   | 17 (27.0)     |              |
| ypN1                   | 3 (27.3)   | 10 (15.9)     |              |
| ypN2                   | 1 (9.1)    | 16 (25.4)     |              |
| ypN3                   | 0 (0)      | 20 (31.7)     |              |
| **ypM status**         |            |               | 0.596        |
| ypM0                   | 11 (100)   | 55 (87.3)     |              |
| ypM1                   | 0 (0)      | 8 (12.7)      |              |
| **Hospital stay (no complication)** | 8.5±2.1 | 9.1±2.6 | 0.562†        |
| **Postoperative complications** |            |               | 0.718        |
| No                     | 9 (81.8)   | 46 (73.0)     |              |
| Yes                    | 2 (18.2)   | 17 (27.0)     |              |

LND, lymph node dissection; LNs, lymph nodes.

*Chi-square.

†Student’s \(t\)-test, mean±standard deviation. Values in parentheses are percentage.

![Fig. 1. Overall survival curves according to ypT status (\(p=0.048\)).](image1)

![Fig. 2. Overall survival curves according to ypN status (\(p=0.003\)).](image2)
response to preoperative treatment regardless of ypN status.

Neoadjuvant CCRTx was more effective than neoadjuvant CTx for tumor regression in gastric cancer. The favorable response rate (ypT0) was 31.6% after CCRTx and only 9.1% after CTx. In addition, the incidence of ypN0 was 47.4% (9 patients) after CCRTx and 27.3% (15 patients) after CTx. The impact of preoperative CTx or CCRTx in esophagogastric junction (EGJ) cancer was observed in several Western studies.\textsuperscript{11,12} Additionally, one phase III study comparing CTx and CCRTx showed a higher complete pathologic response rate in the preoperative CCRTx group than in the preoperative CTx group.\textsuperscript{13} Although these Western studies focused on esophageal and EGJ cancer, the superiority of adding radiation therapy to preoperative CTx may be applied to gastric cancer, too.

However, in this retrospective study, the initial tumor status and the treatment efficacy for CCRTx and CTx in histologic tumor regression of gastric cancer could not be directly compared. Moreover, because the preoperative treatment of the neoadjuvant intent was not routine and the indications of preoperative CCRTx or CTx were not well established in our institute, CTx or CCRTx was done arbitrarily according to the surgeons’ or oncologists’ decision in locally far advanced gastric cancer. Therefore, our data cannot offer conclusive evidence. It can only provide some clues for achieving better survival in advanced gastric cancer, which should be solved by more prospective studies.

The prognosis of patients with a favorable response was poorer than anticipated in our results, because two of our seven patients (28.6%) with complete pathologic response experienced tumor recurrence within a short time. These two patients did not receive adjuvant CTx; however, two patients with ypT0N0 who received adjuvant treatment did not experience tumor recurrence (Table 3). When the tumor was in the advanced stage, despite neoadjuvant treatment, the prognosis was very poor. Tumor recurrence developed rapidly, with the majority recurring within 12 months even after R0 resection. Therefore, postoperative adjuvant treatment may be necessary regardless of the surgical pathology stage. Because of the small number of patients, the survival

| ypT | ypN | Patient No. | Adjuvant CTx | Patient No. | Recurrence No. | Recurrence (%) | Recurrence site | Time to recurrence (months) |
|-----|-----|-------------|--------------|-------------|----------------|----------------|----------------|--------------------------|
| T0  | N0  | 7           | Yes          | 2           | 0              |                |                 |                          |
|     |     |             |              | No          | 5              | 2              | 28.6           | 1 H, 1 L                 | 4.7, 6.1                 |
|     | N1  | 3           | Yes          | 2           | 0              |                |                 |                          |
|     |     |             |              | No          | 1              | 1              | 33.3           | 1 M (H)                 | 6.0                      |
|     | N2  | 1           | Yes          | 1           | 0              |                |                 |                          |
| T1  | N0  | 3           | No           | 0           |                |                |                 |                          |
|     | N3  | 1           | Yes          | 1           | 1              | 100            |                |                          |
|     |     |             |              | No          | 1              | 0              |                |                          |
| T2  | N0  | 5           | Yes          | 4           | 1              | 20.0           | 1 P             |                          |
|     |     |             |              | No          |                |                |                 |                          |
|     | N1  | 3           | Yes          | 1           | 1              | 33.3           | 1 M (P)         | 7.4                      |
| T3  | N0  | 6           | Yes          | 4           | 1              | 33.3           | 2 P             |                          |
|     |     |             |              | No          | 2              | 1              |                |                          |
|     | N1  | 4           | Yes          | 4           | 2              | 50.0           | 2 H             |                          |
|     |     |             |              | No          | 1              | 1              |                |                          |
|     | N2  | 8           | Yes          | 7           | 3              | 50.0           | 3 P             |                          |
|     |     |             |              | No          | 1              | 1              | 1 L             |                          |
|     | N3  | 2           | Yes          | 2           | 1              | 50.0           | 1 L             |                          |
| T4a | N0  | 2           | No           | 2           | 1              | 50.0           | 1 H             |                          |
|     | N1  | 2           | Yes          | 2           | 2              | 100            | 1 P             |                          |
|     |     |             |              | No          |                |                | 1 H             |                          |
|     | N2  | 8           | Yes          | 8           | 2              | 25.0           | 1 H             |                          |
|     |     |             |              | No          |                | 1 M (L)        | 8.8             |                          |
|     | N3  | 9           | Yes          | 8           | 6              | 77.8           | 4 P             |                          |
|     |     |             |              | No          |                | 2 L             | 8.5, 10.3       |                          |
|     | N4  | 1           | Yes          | 1           | 1              | 100            | 1 L             |                          |

H, hematogenous; L, lymphatic; P, peritoneal; M, multiple combined metastasis.
analysis at each stage had some limitations. The rationale for adjuvant CTx in patients with complete pathologic remission is not conclusive; however, this study may offer clues toward improvement in the treatment of advanced gastric cancer with neoadjuvant therapy.

This retrospective study design resulted in several limitations, including the inability to strictly evaluate the initial tumor stage before neoadjuvant treatment and the lack of consistency with respect to the diagnostic modalities and neoadjuvant treatment protocols. It was difficult to determine whether patient survival was better represented by the initial tumor stage or the final pathologic tumor stage. Additionally, the degree of histologic tumor regression by neoadjuvant treatment was not evaluated in all patients. These drawbacks would be overcome with a prospective randomized study.

In summary, concurrent CCRTx rather than CTx alone appeared to be more effective with respect the pathologic response in locally-advanced gastric cancer and postoperative nodal status appeared to reflect patients’ prognoses better than ypT status. Although favorable pathologic response by neoadjuvant treatment was achieved, survival was not as good even after radical surgery. Overall, these results suggest the survival benefit of neoadjuvant treatment regardless of the fact that resectability remains controversial.

ACKNOWLEDGEMENTS

This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science, and Technology (2011-0011301).

REFERENCES

1. Rohatgi PR, Mansfield PF, Crane CH, Wu TT, Sunder PK, Ross WA, et al. Surgical pathology stage by American Joint Commission on Cancer criteria predicts patient survival after preoperative chemoradiation for localized gastric carcinoma. Cancer 2006;107:1475-82.
2. Ajani JA, Mansfield PF, Janjan N, Morris J, Pisters PW, Lynch PM, et al. Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J Clin Oncol 2004;22:2774-80.
3. Becker K, Langer R, Reim D, Novotny A, Meyer zum Buschfelde C, Engel J, et al. Significance of histopathological tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas: a summary of 480 cases. Ann Surg 2011;253:934-9.
4. Ajani JA, Mansfield PF, Crane CH, Wu TT, Lunagomez S, Lynch PM, et al. Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome. J Clin Oncol 2005;23:1237-44.
5. Nakajima T. Gastric cancer treatment guidelines in Japan. Gastric Cancer 2002;5:1-5.
6. Sobin LH, Wittekind CH. TNM Classification of Malignant Tumours. 7th ed. International Union Against Cancer (UICC). New York: Wiley; 2009.
7. An JY, Cheong JH, Hyung WJ, Noh SH. Recent evolution of surgical treatment for gastric cancer in Korea. J Gastric Cancer 2011;11:1-6.
8. Lee JH, Kim KM, Cheong JH, Noh SH. Current management and future strategies of gastric cancer. Yonsei Med J 2012;53:248-57.
9. Sym SJ, Chang HM, Ryu MH, Lee JL, Kim TW, Yook JH, et al. Neoadjuvant docetaxel, capecitabine and cisplatin (DXP) in patients with unresectable locally advanced or metastatic gastric cancer. Ann Surg Oncol 2010;17:1024-32.
10. Lordick F, Stein HJ, Peschel C, Siewert JR. Neoadjuvant therapy for oesophagogastric cancer. Br J Surg 2004;91:540-51.
11. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11-20.
12. Stahl M, Vanhoefer U, Stuschke M, Walz MK, Muller C, Wilke H. Pre-operative sequential chemo- and radiochemotherapy in locally advanced carcinomas of the lower oesophagus and gastro-oesophageal junction. Eur J Cancer 1998;34:668-73.
13. Stahl M, Walz MK, Stuschke M, Lehmann N, Meyer HJ, Riera-Knorrenschild J, et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 2009;27:851-6.